SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Energy Transfer LP engages in natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acquisition, and marketing services to crude oil markets. The Investment in Sunoco LP segment refers to the distribution of motor fuels to independent dealers, distributors, and other commercial customers and the distribution of motor fuels to end-user customers at retail sites. The Investment in USAC segment offers compression services to its customers in connection with infrastructure applications including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. The company was founded by Kelcy L. Warren in 1996 and is headquartered in Dallas, TX.

Energy Transfer LP - Unit

Energy Transfer LP Unit

ETs recent weakness is being debated after a reported quarterly earnings miss, despite higher full-year EBITDA guidance; traders also point to interest-rate concerns, election uncertainty, and questions about whether NGL profits will repeat. Some investors view the pullback as a buying opportunity, citing the distribution and potential data-center gas demand, though several prospective contracts remain unconfirmed.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLakes BLA for sonelokimab in hidradenitis suppurativa is the central focus, with traders watching for the FDAs decision on whether to accept the filing and what review timeline it assigns. Bulls view the regulatory step and broader pipeline as potential value drivers, while skeptics cite clinical and approval risk, managements go-it-alone strategy, and possible future dilution.

ProShares Trust II - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

SCO is drawing attention as traders use the leveraged inverse crude ETF to bet on oils direction amid shifting Iran and Strait of Hormuz conflict and peace-deal expectations. Some expect de-escalation and lower oil prices to lift SCO, while others complain that futures exposure, backwardation and daily-reset decay have caused it to lag crudes moves.

Victoria's Secret & Co. operates as a lingerie, clothing and beauty retailer. It offers bras, panties, lingerie, sleepwear, apparel, sport and swim apparel, and beauty products. The company was founded in 1963 and is headquartered in Reynoldsburg, OH.

Victoria`s Secret & Co

Victorias Secrets turnaround momentum and strong earnings-driven rally, alongside analyst upgrades, are fueling bullish interest and technical-breakout chatter. Traders remain divided, with some citing improving brand demand and guidance while skeptics warn the run-up may be overextended and vulnerable to a pullback.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Competitive J&J bleximenib data has raised concern about future share for Kuras menin inhibitor, with traders debating whether differences in prior venetoclax exposure make the comparison misleading. Some view the selloff as an overreaction and are looking to ASH data for clearer evidence on ziftomenibs frontline potential.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevrons quarterly earnings beat, with unusually strong refining profits amid tight diesel supply and record U.S. refinery throughput, is driving attention. Traders are weighing the stronger cash flow and debt reduction against concerns that refining gains may be temporary, while some are also debating whether the recent rally has run too far.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshires Q3 results are drawing attention, with weaker operating performanceparticularly in insuranceset against a sharp increase in share repurchases. Traders are split between concern over the earnings softness and approval of the buybacks as a sign of management confidence and disciplined capital allocation.

Compound (COMP) is a cryptocurrency and operates on the Ethereum platform. Compound has a current supply of 10,000,000 with 9,999,999.99996583 in circulation. The last known price of Compound is 20.01995221 USD and is up 1.77 over the last 24 hours. It is currently trading on 652 active market(s) with $12,247,660.17 traded over the last 24 hours. More information can be found at https://www.compound.xyz/.

Compound

Traders are focused on Compounds institutional finance push, including a planned institutional market and the v4 roadmap, and many see its capped token supply as a reason to accumulate. Optimism about a breakout contrasts with frustration that COMP has lagged other crypto assets and struggled to hold gains.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowheads RNAi pipeline is drawing attention, particularly ARO-MAPTs early tau-reduction data and positive Phase 3 SHASTA results for plozasiran in severe hypertriglyceridemia. Traders see the results as evidence of broader platform potential, but debate the stocks muted response and speculate about valuation, market trading, and possible acquisition interest.

Air Canada engages in the provision of airline transportation services. Its services cover full-service airline, scheduled passenger and cargo services, serving more than two hundred airports on six continents. It operates through the following geographical segments: Canada, U.S. Transborder, Atlantic, Pacific, and Other. The company was founded on April 11, 1936 and is headquartered in Saint-Laurent, Canada.

Air Canada Inc. - Ordinary Shares (Voting and Variable Voting)

Air Canada Inc.

Speculation that fighting with Iran could resume is driving bearish discussion, with traders warning that an oil-price spike would raise Air Canadas fuel costs and pressure the shares. Others point to the companys share buybacks and argue that lower oil prices would support the airline, but the war and oil scenarios remain uncertain.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sionna Therapeutics, Inc. (SION) Loses 37.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Sionna Therapeutics, Inc. (SION) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SIONPR NewswireNEW YORK, Sept. 24, 2026 NEW YORK, Sept. 24, 2026...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SIONPR NewswireNEW YORK, Sept. 17, 2026 NEW YORK, Sept. 17, 2026...

SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Down

Sionna set to reduce its workforce by 46% after SION-719 fails a key CF study, shifting focus to SION-451 + SION-2222.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION PR Newswire NEW YORK, Sept. 10, 2026 NEW YORK, Sept. 10, 2026...

INVESTIGATION ALERT: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - SION

INVESTIGATION ALERT: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - SION INVESTIGATION ALERT: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION PR Newswire NEW YORK, Aug. 27, 2026 NEW YORK, Aug. 27, 2026...

Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics

Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics PR Newswire SAN DIEGO, Aug. 19, 2026 SAN DIEGO, Aug. 19, 2026 /PRNewswire/ -- Shareholder rights law...

Sionna Therapeutics (SION) Securities Investigation Notice - Levi & Korsinsky

Sionna Therapeutics (SION) Securities Investigation Notice - Levi & Korsinsky Sionna Therapeutics (SION) Securities Investigation Notice - Levi & Korsinsky PR Newswire NEW YORK, Aug. 19, 2026 Sionna Therapeutics Shares Lost Roughly 90% of Their Value After Phase 2a PreciSION CF Trial of SION-719...

Investigation Launched into Sionna Therapeutics, Inc. (SION), Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of United States federal securities laws involving Sionna Therapeutics, Inc. (NASDAQ: SION). If you have information that could assist in the Sionna Therapeutics investigation or if you are a Sionna Therapeutics...

Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The firm engages in researching, developing and commercializing novel medicines for cystic fibrosis. It is focused on advancing a pipeline of small molecules and complementary CFTR modulators designed to deliver transformative clinical outcomes and improve the quality of life for individuals living with cystic fibrosis. The company was founded by Greg Hurlbut and Mark Munson in August 2019 and is headquartered in Waltham, MA.

Sionna Therapeutics Inc.

SION Stock On Track For Worst Day Ever After 90% Drop — What’s Driving The Selloff?

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Sionna said it will not advance SION-719 as an add-on therapy with Trifakta anymore.&nbsp;</li><li>Stifel downgraded Sionna to Hold from Buy with a $7 target, from $55, saying it was “disappointed and very surprised” by the failure.&nbsp;</li><li>Sionna ended the second quarter with about $268 million in cash and said it plans steps to preserve capital while assessing its path forward.</li></ul>Shares of Sionna Therapeutics (SION) plunged roughly 92% on Monday after the biotech firm reported that its experimental cystic fibrosis drug failed to deliver meaningful benefits in a mid-stage trial, prompting it to abandon plans for the treatment as an add-on to existing standard care.Sionna said its mid-stage trial of SION-719 in 15 adults with cystic fibrosis already taking Vertex’s (VRTX) Trikafta failed to meet its main goal. The drug barely lowered sweat chloride levels—a key marker of improved protein function—showing a minor difference versus placebo that was not statistically significant.The stock is now on track for its worst day ever, if losses hold. VRTX stock, meanwhile, rose 7%, eyeing its best day since early March. &nbsp;<h2 class="st-heading-2">Trial Miss Ends One Program; Another Remains Under Review</h2>Cystic fibrosis is a genetic condition that causes thick mucus to build up in the lungs and other organs, leading to breathing problems and infections. Trikafta is the leading approved treatment. Sionna had hoped SION-719 could further improve outcomes when added on top, but the company said it will not advance the drug in that role anymore after the trial outcomes.The drug was generally well tolerated over 14 days, with mostly mild-to-moderate side effects and no serious issues. Sionna noted possible complicating factors, including unexpected variability in patients’ sweat chloride readings and differences in Trikafta levels during the study periods. It is still analyzing those results.In a separate early-stage study in healthy volunteers, combinations involving Sionna’s related drug SION-451 met safety, tolerability, and exposure goals. The company said it is evaluating next steps for a combination of SION-451 with SION-2222.“We are disappointed in the unexpected results from the Phase 2a trial,” said CEO Mike Cloonan. “We are further evaluating the data to decide on next steps for the SION-451 dual combination.”Sionna ended the second quarter with about $268 million in cash and said it plans steps to preserve capital while assessing its path forward.<h2 class="st-heading-2">Analysts Weigh On VRTX, SION</h2>Wall Street quickly weighed in. Bank of America raised its price target on Vertex to $672 from $605 and kept a ‘Buy’ rating, saying Sionna’s trial miss removes an overhang that investors had viewed as a potential threat to Vertex’s cystic fibrosis franchise.Raymond James downgraded Sionna to ‘Market Perform’ from ‘Strong Buy’, calling the trial a clear failure and citing added uncertainty from possible drug interactions and safety signals.Wedbush cut Sionna to ‘Neutral’ from ‘Outperform’ and lowered its target to $5 from $53, saying that questions remain about the platform’s potential, while shifting any SION-451 launch possibility to 2033.Stifel downgraded Sionna to 'Hold' from 'Buy' with a $7 target, from $55, saying it was “disappointed and very surprised” by the failure and sees no clear Buy case until management explains what went wrong.<h2 class="st-heading-2">How Did SION Retail Traders React?</h2>On Stocktwits, retail sentiment around SION stock jumped from 'neutral' to 'extremely bullish' territory over the past 24 hours, while message volume rose from 'normal' to 'extremely high' levels.A Stocktwits user highlighted the company’s cash position and termed the stock a steal at current prices.<stembedurl>https://www.stocktwits.com/Invest2live/message/661444973</stembedurl>Another user took a more pessimistic take and wrote, “It may climb from here, but the story is dead.”<stembedurl>https://www.stocktwits.com/CH_Expat/message/661432094</stembedurl><a href="https://stocktwits.com/symbol/SION">SION stock</a> has fallen about 89% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/replimune-s-first-commercial-drug-arrives-with-a-2027-cash-cliff-and-2030-finish-line/cZogtqwRJ96">Replimune’s First Commercial Drug Arrives—With A 2027 Cash Cliff And 2030 Finish Line</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sionna Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Sionna said it will not advance SION-719 as an add-on therapy with Trifakta anymore. Stifel downgraded Sionna to Hold from Buy with a $7 target, from $55, saying it was “disappointed and very surprised” by the failure. Sionna ended the second quarter with

Sionna said on Monday that its mid-stage trial of SION-719 in 15 adults with cystic fibrosis already taking Vertex’s Trikafta failed to meet its main goal.


Sionna Therapeutics Inc

Vertex Pharmaceuticals, Inc.

Vanguard Total Stock Market ETF

SPDR S&P Biotech ETF

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

$SION hey there new all time low today really been on a downtrend the company has 260 million in cash and no debt so it's basically trading at less than cash still down every day

Feed

News

Sentiment

Earnings

Fundamentals

Info

SION Sionna Therapeutics Inc

Fundamentals

Latest SION News